LumiraDx

34 articles about LumiraDx

• LumiraDx to Announce Second Quarter Financial Results and Host Quarterly Conference Call on August 24

  8/16/2023

  LumiraDx Limited  (Nasdaq: LMDX), a next-generation point of care (POC) diagnostics company, announced it will release its second quarter financial results on Thursday, August 24, 2023.

• LumiraDx’s Point of Care Diagnostics Group Continues Commercial Expansion Announcing a Distribution Agreement with Axonlab for its LumiraDx Platform and Tests

  7/31/2023

  LumiraDx Limited announced that it signed a commercial distribution agreement with Axon Lab AG for the commercialization of its LumiraDx Platform and diagnostic tests to include exclusive distribution rights in Switzerland and additional non-exclusive distribution rights in further European countries to include and starting in Germany.

• LumiraDx Submits First 510(k) Application to the FDA for COVID Ultra Test

  6/30/2023

  LumiraDx Limited, a leading innovator in diagnostic technologies, announced the submission of its first 510 application to the U.S. Food and Drug Administration for the clearance of its ground-breaking 5-minute COVID Ultra Test.

• LumiraDx Reports First Quarter 2023 Results

  5/16/2023

  LumiraDx Limited (NASDAQ: LMDX), a next-generation point of care (POC) diagnostics company, today announced financial results for its first quarter ended March 31, 2023.

• LumiraDx Receives Nasdaq Notification Regarding Minimum Bid Price Deficiency

  4/24/2023

  LumiraDx Limited announced that it has received notification from The Nasdaq Stock Market LLC that it is not in compliance with the minimum bid price requirement in Nasdaq Listing Rule 5450 for continued listing on the Nasdaq Global Market, since the closing bid price for the Company’s common shares on the Nasdaq Global Market was below US$1.00 for 30 consecutive trading days.

• LumiraDx Announces Strategic Refocus and Cost Restructuring Program

  4/6/2023

  LumiraDx Limited announced its Strategic Refocus and Cost Restructuring Program aimed at reducing its scale and operations to pre-pandemic levels and to further evolve LumiraDx into an agile organization with a clear focus on the areas with the greatest potential.

• LumiraDx Reports Fourth Quarter and Full Year 2022 Results

  3/21/2023

  LumiraDx Limited today announced financial results for its fourth quarter and full year ended December 31, 2022.

• LumiraDx to Announce Fourth Quarter and Full Year 2022 Financial Results and Host Quarterly Conference Call on March 21

  3/14/2023

  LumiraDx Limited announced it will release its fourth quarter and full year 2022 financial results on Tuesday, March 21st , 2023.

• LumiraDx to Present at Raymond James Institutional Investors Conference

  3/3/2023

  LumiraDx Limited will be presenting at the Raymond James Institutional Investors Conference on Tuesday, March 7th, 2023 at 4:35pm ET. Webcast link below.

• LumiraDx Regains Compliance with Nasdaq Continued Listing Requirements - February 17, 2023

  2/17/2023

  LumiraDx Limited announced that it has received confirmation from The Nasdaq Stock Market LLC that it has regained compliance with the minimum bid price requirement under Nasdaq Listing Rule 5450.

• LumiraDx Announces Receipt of Nasdaq Notification Letter Regarding Minimum Bid Price Deficiency

  1/31/2023

  LumiraDx Limited announced that it has received notification from The Nasdaq Stock Market LLC that it is not in compliance with the minimum bid price requirement in Nasdaq Listing Rule 5450 for continued listing on the Nasdaq Global Market, since the closing bid price for the Company’s common shares on the Nasdaq Global Market was below US$1.00 for 30 consecutive trading days.

• LumiraDx Announces New Investment for Ongoing Development of its Point of Care Molecular Tuberculosis Test

  12/14/2022

  LumiraDx Limited, a next-generation point of care diagnostics company, announced it has received $14.2M in grants from the Bill & Melinda Gates Foundation for ongoing development of its point of care molecular tuberculosis testing system.

• Latest Clinicians’ U.S. Survey Identifies Point of Care Testing (POCT) as a Way to Address Healthcare Bandwidth Pressures and Anticipates Future Growth of POCT in Community Testing Centers

  12/8/2022

  LumiraDx Limited, a next-generation point of care diagnostics company, announced findings from its second annual “Point of Care Diagnostics: A Clinician's View” U.S. survey, designed to understand physicians’ perspectives on the latest point of care diagnostics technologies available.

• LumiraDx Continues Commercial Expansion of its Rapid Microfluidic Immunoassay HbA1c Test

  11/14/2022

  LumiraDx Limited, a next-generation point of care diagnostics company, announced the continued commercial expansion of its HbA1c test, for professional use across multiple care settings.

• LumiraDx Reports Third Quarter 2022 ResultsProgress on Near-Term Growth Opportunities and Cost Savings

  11/9/2022

  LumiraDx Limited today announced operational and financial results for the third quarter ended September 30, 2022.

• LumiraDx to Announce Third Quarter Financial Results and Host Quarterly Conference Call on November 9

  11/2/2022

  LumiraDx Limited  (Nasdaq:  LMDX ), a next-generation point of care (POC) diagnostics company, announced it will release its third quarter financial results on Wednesday, November 9th , 2022.

• LumiraDx Reports Second Quarter 2022 ResultsStrong Pipeline Progress and Commercialization Priorities for Newly Authorized Products

  8/18/2022

  LumiraDx Limited (Nasdaq: LMDX), a next-generation point of care (POC) diagnostics company, today announced operational and financial results for the second quarter ended June 30, 2022.

• LumiraDx to Announce Second Quarter Financial Results and Host Quarterly Conference Call on August 18

  8/11/2022

  LumiraDx Limited  (Nasdaq:  LMDX ), a next-generation point of care (POC) diagnostics company, announced it will release its second quarter financial results on Thursday, August 18th, 2022.

• LumiraDx Announces Pricing of Public Offering of Common Shares and Concurrent Private Placement

  7/21/2022

  LumiraDx Limited (Nasdaq: LMDX), a next-generation point of care (POC) diagnostics company, today announced the pricing of its underwritten public offering of 43,000,000 common shares at a price to the public of $1.75 per share.

• LumiraDx Announces Proposed Public Offering of Common Shares

  7/19/2022

  LumiraDx Limited (Nasdaq: LMDX), a next-generation point of care (POC) diagnostics company, today announced that it has commenced an underwritten public offering of 40,000,000 common shares.